ZA200006817B - Combination therapy for treatment of Bipolar Disorders. - Google Patents
Combination therapy for treatment of Bipolar Disorders. Download PDFInfo
- Publication number
- ZA200006817B ZA200006817B ZA200006817A ZA200006817A ZA200006817B ZA 200006817 B ZA200006817 B ZA 200006817B ZA 200006817 A ZA200006817 A ZA 200006817A ZA 200006817 A ZA200006817 A ZA 200006817A ZA 200006817 B ZA200006817 B ZA 200006817B
- Authority
- ZA
- South Africa
- Prior art keywords
- olanzapine
- component
- composition
- group
- substance
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 36
- 208000020925 Bipolar disease Diseases 0.000 title claims description 33
- 238000002648 combination therapy Methods 0.000 title description 2
- 229960005017 olanzapine Drugs 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 37
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 37
- 150000001875 compounds Chemical class 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 21
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 20
- 229960002464 fluoxetine Drugs 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 19
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 12
- 239000001961 anticonvulsive agent Substances 0.000 claims description 12
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims description 12
- 239000003693 atypical antipsychotic agent Substances 0.000 claims description 11
- 229940127236 atypical antipsychotics Drugs 0.000 claims description 11
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 10
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 9
- 229960003965 antiepileptics Drugs 0.000 claims description 9
- 229910052744 lithium Inorganic materials 0.000 claims description 9
- 208000024714 major depressive disease Diseases 0.000 claims description 9
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 claims description 9
- 230000001773 anti-convulsant effect Effects 0.000 claims description 8
- 229960004170 clozapine Drugs 0.000 claims description 8
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 8
- 229960004431 quetiapine Drugs 0.000 claims description 8
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims description 8
- 208000028683 bipolar I disease Diseases 0.000 claims description 7
- 229960001534 risperidone Drugs 0.000 claims description 7
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 7
- 229960000652 sertindole Drugs 0.000 claims description 7
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 claims description 7
- 229960000607 ziprasidone Drugs 0.000 claims description 7
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims description 7
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 claims description 6
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims description 6
- 208000020401 Depressive disease Diseases 0.000 claims description 6
- 208000025307 bipolar depression Diseases 0.000 claims description 6
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229960002866 duloxetine Drugs 0.000 claims description 6
- 201000003104 endogenous depression Diseases 0.000 claims description 6
- 229960000600 milnacipran Drugs 0.000 claims description 6
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 6
- 229960004688 venlafaxine Drugs 0.000 claims description 6
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 5
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 5
- 238000002441 X-ray diffraction Methods 0.000 claims description 5
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims description 5
- 229960004038 fluvoxamine Drugs 0.000 claims description 5
- 229960002870 gabapentin Drugs 0.000 claims description 5
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims description 5
- 229960001848 lamotrigine Drugs 0.000 claims description 5
- 229960002296 paroxetine Drugs 0.000 claims description 5
- 229960002073 sertraline Drugs 0.000 claims description 5
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 229960000604 valproic acid Drugs 0.000 claims description 5
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims description 4
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims description 4
- 229960001653 citalopram Drugs 0.000 claims description 4
- 229960004394 topiramate Drugs 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 description 8
- 208000028017 Psychotic disease Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 206010026749 Mania Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010061334 Partial seizures Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 1
- WSEQXVZVJXJVFP-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 1
- ZVAPWJGRRUHKGP-UHFFFAOYSA-N 1h-1,5-benzodiazepine Chemical compound N1C=CC=NC2=CC=CC=C12 ZVAPWJGRRUHKGP-UHFFFAOYSA-N 0.000 description 1
- CJOFXWAVKWHTFT-UHFFFAOYSA-N 2-[[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine Chemical compound COCCCCC(=NOCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000027776 Extrapyramidal disease Diseases 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 208000020186 Schizophreniform disease Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- ZEUITGRIYCTCEM-UHFFFAOYSA-N duloxetine Chemical compound C=1C=CC2=CC=CC=C2C=1OC(CCNC)C1=CC=CS1 ZEUITGRIYCTCEM-UHFFFAOYSA-N 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- GJJFMKBJSRMPLA-UHFFFAOYSA-N milnacipran Chemical compound C=1C=CC=CC=1C1(C(=O)N(CC)CC)CC1CN GJJFMKBJSRMPLA-UHFFFAOYSA-N 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000000966 norepinephrine reuptake Effects 0.000 description 1
- 230000012154 norepinephrine uptake Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 230000013275 serotonin uptake Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- -1 valproate ion Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Electrotherapy Devices (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8712698P | 1998-05-29 | 1998-05-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200006817B true ZA200006817B (en) | 2002-02-21 |
Family
ID=22203275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200006817A ZA200006817B (en) | 1998-05-29 | 2000-11-21 | Combination therapy for treatment of Bipolar Disorders. |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0966967A3 (fr) |
| JP (1) | JP2002516864A (fr) |
| KR (1) | KR20010043731A (fr) |
| CN (1) | CN1302207A (fr) |
| AU (1) | AU756468B2 (fr) |
| BR (1) | BR9911068A (fr) |
| CA (1) | CA2332408A1 (fr) |
| CZ (1) | CZ20004280A3 (fr) |
| EA (1) | EA003611B1 (fr) |
| HR (1) | HRP20000798A2 (fr) |
| HU (1) | HUP0102511A2 (fr) |
| IL (1) | IL139591A0 (fr) |
| NO (1) | NO20005884L (fr) |
| NZ (1) | NZ507981A (fr) |
| PL (1) | PL344304A1 (fr) |
| SK (1) | SK17492000A3 (fr) |
| TR (1) | TR200003525T2 (fr) |
| WO (1) | WO1999062522A1 (fr) |
| ZA (1) | ZA200006817B (fr) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6960577B2 (en) | 1998-05-22 | 2005-11-01 | Eli Lilly And Company | Combination therapy for treatment of refractory depression |
| US6174882B1 (en) * | 1998-11-23 | 2001-01-16 | Sepracor Inc. | 2-hydroxymethylolanzapine compositions and methods |
| UA77650C2 (en) * | 1999-12-06 | 2007-01-15 | Lundbeck & Co As H | Use of serotonin reuptake inhibitor in combination with deramcyclane |
| FR2802101B1 (fr) * | 1999-12-10 | 2003-02-28 | Aventis Pharma Sa | Association de cymemazine et d'un neuroleptique atypique |
| EP1309325A1 (fr) | 2000-08-02 | 2003-05-14 | Ortho-McNeil Pharmaceutical, Inc. | Derives anticonvulsivants utilises dans le traitement de la depression |
| AU2002232470B2 (en) * | 2001-01-02 | 2005-11-03 | Pharmacia & Upjohn Company Llc | New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents |
| EP1404342A1 (fr) * | 2001-04-26 | 2004-04-07 | Ortho-Mcneil Pharmaceutical, Inc. | Traitement des troubles psychotiques comportant une co-therapie avec des derives anti-convulsions et des anti-psychotiques atypiques |
| EP1551393A4 (fr) | 2002-07-30 | 2010-06-16 | Peter Migaly | Combinaison de therapie pour la depression, la prevention du suicide et divers troubles medicaux et psychiatriques |
| US7410759B2 (en) | 2002-11-01 | 2008-08-12 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for diagnosing and treating mood disorders |
| AR042806A1 (es) | 2002-12-27 | 2005-07-06 | Otsuka Pharma Co Ltd | Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo |
| EP1723957A3 (fr) | 2002-12-27 | 2013-01-23 | Otsuka Pharmaceutical Co., Ltd. | Dérivés de carbostyrile et inhibiteurs de réabsorption de la sérotonine pour le traitement des troubles de l'humeur |
| FR2851163B1 (fr) * | 2003-02-14 | 2007-04-27 | Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament | |
| JP2007516955A (ja) * | 2003-05-16 | 2007-06-28 | ファイザー・プロダクツ・インク | 双極性障害および関連症候の治療 |
| EP2601953A1 (fr) | 2003-05-23 | 2013-06-12 | Otsuka Pharmaceutical Co., Ltd. | Dérives de carbostyrile et psychorégulateurs pour traiter les troubles de l'humeur |
| WO2005053703A1 (fr) | 2003-12-02 | 2005-06-16 | Leslie James Sheldon | Polytherapie contre la demence, la depression et l'apathie |
| EP1696896A2 (fr) * | 2003-12-15 | 2006-09-06 | H. Lundbeck A/S | Combinaison d'un inhibiteur de reabsorption de la serotonine et d'un antagoniste du recepteur de l'histamine 3, agoniste inverse ou partiel |
| EP1737473A4 (fr) * | 2004-04-19 | 2009-08-26 | Noven Therapeutics Llc | Combinaisons de lithium et utilisations associees |
| CA2569411A1 (fr) * | 2004-06-04 | 2005-12-22 | Mood Management Sciences, Llc | Compositions et methodes de traitement des troubles de l'humeur |
| MY147767A (en) | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
| CA2571243A1 (fr) | 2004-06-21 | 2006-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Genes et voies exprimes de maniere differentielle dans des troubles bipolaires et/ou troubles depressifs majeurs |
| EP1951908B1 (fr) | 2005-11-12 | 2013-08-07 | The Board of Trustees of The Leland Stanford Junior University | Méthodes associées au fgf2 pour diagnostiquer et traiter une dépression |
| US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
| US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
| TW200812573A (en) | 2006-05-19 | 2008-03-16 | Janssen Pharmaceutica Nv | Co-therapy for the treatment of epilepsy and related disorders |
| US20080199866A1 (en) * | 2006-10-10 | 2008-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Snp detection and other methods for characterizing and treating bipolar disorder and other ailments |
| GB0814466D0 (en) * | 2008-08-07 | 2008-09-10 | Rosemont Pharmaceuticals Ltd | Sertraline composition |
| CA2891122C (fr) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methodes et compositions pour le traitement de la schizophrenie |
| CN108926569A (zh) * | 2018-08-24 | 2018-12-04 | 山西医科大学第医院 | 一种非典型抗精神病药物组合物 |
| CN108938645A (zh) * | 2018-08-24 | 2018-12-07 | 山西医科大学第医院 | 一种抗精神病药物组合物 |
| CN109464436A (zh) * | 2019-01-10 | 2019-03-15 | 高智玉 | 西酞普兰或艾司西酞普兰分别和喹硫平联合在制备治疗精神障碍类疾病的复方制剂中的应用 |
| CN110151718A (zh) * | 2019-06-13 | 2019-08-23 | 厦门医学院 | 一种奥氮平口腔崩解片及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8072691A (en) * | 1990-06-28 | 1992-01-23 | Beecham Group Plc | Pharmaceutical preparations |
| WO1997033577A1 (fr) * | 1996-03-11 | 1997-09-18 | Eli Lilly And Company | Methode de traitement des troubles bipolaires |
| CN1146421C (zh) * | 1996-03-25 | 2004-04-21 | 伊莱利利公司 | 治疗疼痛的组合物以及药物在制备所述组合物中的应用 |
| ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
-
1999
- 1999-05-21 EA EA200001244A patent/EA003611B1/ru not_active IP Right Cessation
- 1999-05-21 SK SK1749-2000A patent/SK17492000A3/sk unknown
- 1999-05-21 KR KR1020007013060A patent/KR20010043731A/ko not_active Application Discontinuation
- 1999-05-21 HU HU0102511A patent/HUP0102511A2/hu unknown
- 1999-05-21 WO PCT/US1999/011314 patent/WO1999062522A1/fr not_active Application Discontinuation
- 1999-05-21 CA CA002332408A patent/CA2332408A1/fr not_active Abandoned
- 1999-05-21 NZ NZ507981A patent/NZ507981A/en unknown
- 1999-05-21 JP JP2000551778A patent/JP2002516864A/ja not_active Withdrawn
- 1999-05-21 BR BR9911068-7A patent/BR9911068A/pt not_active IP Right Cessation
- 1999-05-21 EP EP99303968A patent/EP0966967A3/fr not_active Withdrawn
- 1999-05-21 CN CN99806479A patent/CN1302207A/zh active Pending
- 1999-05-21 CZ CZ20004280A patent/CZ20004280A3/cs unknown
- 1999-05-21 TR TR2000/03525T patent/TR200003525T2/xx unknown
- 1999-05-21 AU AU40088/99A patent/AU756468B2/en not_active Ceased
- 1999-05-21 PL PL99344304A patent/PL344304A1/xx unknown
- 1999-05-21 IL IL13959199A patent/IL139591A0/xx unknown
-
2000
- 2000-11-20 HR HR20000798A patent/HRP20000798A2/hr not_active Application Discontinuation
- 2000-11-21 ZA ZA200006817A patent/ZA200006817B/en unknown
- 2000-11-21 NO NO20005884A patent/NO20005884L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CZ20004280A3 (cs) | 2001-09-12 |
| CA2332408A1 (fr) | 1999-12-09 |
| AU756468B2 (en) | 2003-01-16 |
| EA200001244A1 (ru) | 2001-06-25 |
| NZ507981A (en) | 2003-10-31 |
| IL139591A0 (en) | 2002-02-10 |
| EP0966967A3 (fr) | 2000-05-31 |
| CN1302207A (zh) | 2001-07-04 |
| PL344304A1 (en) | 2001-10-22 |
| KR20010043731A (ko) | 2001-05-25 |
| NO20005884D0 (no) | 2000-11-21 |
| SK17492000A3 (sk) | 2002-04-04 |
| EA003611B1 (ru) | 2003-06-26 |
| HUP0102511A2 (hu) | 2001-11-28 |
| TR200003525T2 (tr) | 2001-04-20 |
| JP2002516864A (ja) | 2002-06-11 |
| NO20005884L (no) | 2001-01-24 |
| AU4008899A (en) | 1999-12-20 |
| WO1999062522A1 (fr) | 1999-12-09 |
| BR9911068A (pt) | 2001-02-06 |
| HRP20000798A2 (en) | 2001-10-31 |
| EP0966967A2 (fr) | 1999-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200006817B (en) | Combination therapy for treatment of Bipolar Disorders. | |
| US20080107756A1 (en) | Lithium combinations, and uses related thereto | |
| US9808455B2 (en) | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline | |
| CA2332814C (fr) | Therapie combinee de traitement de la depression resistante | |
| US20030027817A1 (en) | Combination therapy for treatment of bipolar disorders | |
| JP2006528676A (ja) | 非定形型抗精神病薬と、ｇａｂａ調節薬及び／又は抗痙攣薬の治療上の組合せ | |
| JP2008542378A (ja) | 精神病性障害を管理する方法および組成物 | |
| JP2008536946A (ja) | うつ病の処置または予防のための新規の治療的組み合わせ | |
| MX2008012094A (es) | Nuevas combinaciones terapeuticas para el tratamiento de la depresion. | |
| US6960577B2 (en) | Combination therapy for treatment of refractory depression | |
| CN104955483A (zh) | 用低剂量药剂治疗抑郁症和其它疾病 | |
| JP2019147843A (ja) | 吃音を治療するための融合ベンズアゼピン | |
| MXPA02005380A (es) | Tratamiento de combinacion para trastornos del sueno, incluyendo la apnea del sueno. | |
| JP2010523640A5 (fr) | ||
| RU2352336C2 (ru) | Азенапин для лечения шизофрении у пациентов с избыточной массой тела или предрасположенностью к избыточной массе тела | |
| JP2007503424A (ja) | 抗炎症剤として有用なα−アミノアミド誘導体 | |
| MXPA00011354A (en) | Combination therapy for treatment of bipolar disorders | |
| Tarsy | Miscellaneous drug-induced movement disorders | |
| Joffe et al. | MOOD-STABILIZING AGENTS | |
| JP2005060286A (ja) | 統合失調症の治療 |